Zenith Technologies and GE Healthcare Life Sciences strike biopharma alliance
The combined offering is aimed at helping biopharmaceutical manufacturers increase productivity, improve efficiency and reduce costs.
Zenith Technologies and GE Healthcare’s Life Sciences business have announced a collaboration to support biopharmaceutical manufacturing deployment.
As part of the partnership, Zenith Technologies’ methodologies, systems and libraries will be offered as a service to GE Healthcare’s clients in bioprocessing. The combined offering is aimed at helping biopharmaceutical manufacturers increase productivity, improve efficiency and reduce costs.
The two companies will integrate process control systems, manufacturing execution system (MES) solutions and other supporting technologies with GE Healthcare’s start-to-finish technologies and solutions for the biopharmaceutical manufacturing industry.
Jan Makela, general manager at BioProcess GE Healthcare said: "The development of our KUBio modular manufacturing facilities and FlexFactory single-use manufacturing platform was fuelled by the need for customers to deploy biopharmaceutical manufacturing capacity more quickly and at a lower cost.
“Implementing these advanced technology platforms requires automation expertise for which we partner with a number of world class companies. With Zenith Technologies’ expertise in automation integration and customer support, we will be able to offer more choice to customers.”
Brendan O’Regan, founder at Zenith Technologies, said: “This is a significant milestone in our development and ushers in a new era of opportunity for both companies.
“GE offers an unprecedented solution to our pharmaceutical customers to help rapidly deploy capacity and significantly reduce time to market. Combined with our manufacturing software systems and on the ground, global support services, we can help biopharmaceutical manufacturers improve their processes and ultimately increase their competitiveness.”
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.